5 news items
JP Morgan Maintains Overweight on Repligen, Lowers Price Target to $200
RGEN
2 May 24
JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers the price target from $230 to $200.
Repligen Reports First Quarter 2024 Financial Results
RGEN
1 May 24
said, "We delivered a solid first quarter, with revenue of $151 million and are on track to achieving our first half sales target of $300 to $310
Repligen Reports Fourth Quarter and Full Year 2023 Financial Results
RGEN
21 Feb 24
-yearClosed acquisition of mixing innovator Metenova AB, expanding our Fluid Management offering; achieved revenue target
Earnings Scheduled For February 21, 2024
ACVA
ADI
AGI
21 Feb 24
) is projected to report quarterly earnings at $0.26 per share on revenue of $83.85 million.
• Target Hospitality
Keybanc Maintains Overweight on Repligen, Raises Price Target to $220
RGEN
15 Feb 24
Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $210 to $220.
- Prev
- 1
- Next